Swiss National Bank Halozyme Therapeutics, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 248,600 shares of HALO stock, worth $11.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

248,600

Previous 249,900 0.52%

Holding current value

$11.9 Million

Previous $13.1 Million 8.7%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$51.3 - $64.42 $66,690 - $83,746	-1,300 Reduced 0.52%	248,600 $14.2 Million
Q2 2024 Aug 08, 2024	SELL	$37.81 - $52.4 $415,910 - $576,400	-11,000 Reduced 4.22%	249,900 $13.1 Million
Q1 2024 May 07, 2024	BUY	$33.68 - $41.95 $30,312 - $37,755	900 Added 0.35%	260,900 $10.6 Million
Q4 2023 Feb 06, 2024	SELL	$33.32 - $42.1 $979,608 - $1.24 Million	-29,400 Reduced 10.16%	260,000 $9.61 Million
Q3 2023 Nov 08, 2023	SELL	$36.46 - $44.03 $196,884 - $237,762	-5,400 Reduced 1.83%	289,400 $11.1 Million
Q2 2023 Aug 09, 2023	BUY	$30.28 - $38.74 $90,840 - $116,220	3,000 Added 1.03%	294,800 $10.6 Million
Q1 2023 May 10, 2023	SELL	$32.86 - $55.7 $1.34 Million - $2.27 Million	-40,800 Reduced 12.27%	291,800 $11.1 Million
Q4 2022 Feb 08, 2023	BUY	$40.06 - $59.44 $220,330 - $326,920	5,500 Added 1.68%	332,600 $18.9 Million
Q3 2022 Nov 09, 2022	BUY	$38.53 - $51.78 $104,031 - $139,806	2,700 Added 0.83%	327,100 $12.9 Million
Q2 2022 Aug 09, 2022	BUY	$37.35 - $48.3 $306,270 - $396,060	8,200 Added 2.59%	324,400 $14.3 Million
Q1 2022 May 09, 2022	BUY	$31.97 - $41.06 $594,642 - $763,716	18,600 Added 6.25%	316,200 $12.6 Million
Q4 2021 Feb 08, 2022	SELL	$31.82 - $40.75 $41,366 - $52,975	-1,300 Reduced 0.43%	297,600 $12 Million
Q3 2021 Nov 08, 2021	BUY	$38.47 - $46.42 $600,132 - $724,152	15,600 Added 5.51%	298,900 $12.2 Million
Q2 2021 Aug 06, 2021	SELL	$38.84 - $51.31 $392,284 - $518,231	-10,100 Reduced 3.44%	283,300 $12.9 Million
Q1 2021 May 07, 2021	SELL	$39.51 - $51.45 $35,559 - $46,305	-900 Reduced 0.31%	293,400 $12.2 Million
Q4 2020 Feb 05, 2021	BUY	$25.81 - $43.62 $28,391 - $47,982	1,100 Added 0.38%	294,300 $12.6 Million
Q2 2020 Aug 05, 2020	BUY	$16.25 - $26.81 $609,375 - $1.01 Million	37,500 Added 14.67%	293,200 $7.86 Million
Q1 2020 May 08, 2020	BUY	$13.9 - $21.83 $51,430 - $80,771	3,700 Added 1.47%	255,700 $4.6 Million
Q4 2019 Feb 06, 2020	BUY	$14.93 - $19.53 $82,115 - $107,415	5,500 Added 2.23%	252,000 $4.47 Million
Q3 2019 Nov 12, 2019	BUY	$15.2 - $17.69 $54,720 - $63,684	3,600 Added 1.48%	246,500 $3.82 Million
Q2 2019 Aug 02, 2019	BUY	$14.75 - $17.26 $85,550 - $100,108	5,800 Added 2.45%	242,900 $4.17 Million
Q1 2019 May 10, 2019	BUY	$13.94 - $17.58 $104,550 - $131,850	7,500 Added 3.27%	237,100 $3.82 Million
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $47,988 - $67,176	3,600 Added 1.59%	229,600 $3.36 Million
Q3 2018 Nov 08, 2018	BUY	$16.68 - $18.41 $58,380 - $64,435	3,500 Added 1.57%	226,000 $4.11 Million
Q1 2018 May 04, 2018	BUY	$17.06 - $21.2 $83,594 - $103,880	4,900 Added 2.25%	222,500 $4.36 Million
Q4 2017 Feb 07, 2018	BUY	$16.75 - $20.8 $185,925 - $230,880	11,100 Added 5.38%	217,600 $4.41 Million
Q3 2017 Nov 03, 2017	BUY	$11.76 - $17.4 $2.43 Million - $3.59 Million	206,500	206,500 $3.59 Million

Others Institutions Holding HALO

# of Institutions

544

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.66B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Halozyme Therapeutics, Inc. Transaction History